Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3227-3239

  Zhang, Kunchi ^a   Lv, Shaowa ^a   Li, Xiuyan ^a   Feng, Yufei ^a   Li, Xin ^a   Liu, Lu ^a   Li, Shuang ^a   Li, Yongji ^a  

^a HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Central composite design; In vitro release; Nanostructured lipid carriers; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; GENTIOPICRIN; GLYCEROL STEARATE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OLEANOLIC ACID; POLOXAMER; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER PROTECTION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

CENTRAL COMPOSITE DESIGN; IN VITRO RELEASE; NANOSTRUCTURED LIPID CARRIERS; PHARMACOKINETICS;

ANIMALS; CARBON TETRACHLORIDE; DRUG-INDUCED LIVER INJURY; FEMALE; IRIDOID GLUCOSIDES; LIPIDS; LIVER; MALE; MICE; NANOSTRUCTURES; OLEANOLIC ACID; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883033005     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S45031     Document Type: Article

References (25)

1. Kondo Y, Takano F, Hojo H. Suppression of chemically and immunologically induced hepatic injuries by gentiopicroside in mice. Planta Med. 1994;60:414-416.
2. Liu YP, Hartley PD, Liu J. Protection against carbon tetrachloride hepatotoxicity by oleanolic acid is not mediated through metallothionein. Toxicol Lett. 1998;95:77-85.
3. Jeong HG. Inhibition of cytochrome P450 2E1 expression by oleanolic acid: hepatoprotective effects against carbon tetrachloride-induced hepatic injury. Toxicol Lett. 1999;105:215-222.
4. Wang MT, Jin Y, Yang YX, et al. In vivo biodistribution, antiinflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system. Int J Nanomedicine. 2010;5:487-497.
5. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:131-155.
6. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242: 121-128.
7. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Tech. 2011;12:62-76.
8. Luo QH, Zhao JM, Zhang XR, et al. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403:185-191.
9. Shah P, Desai P, Channer D, et al. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release. 2012;161:735-746.
10. Jia LJ, Shen JY, Zhang DR, et al. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol. 2012;50:523-529.
11. Eskandari S, Varshosaz J, Minaiyan M, et al. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine. 2011;6:363-371.
12. Guo CY, Yang CF, Li QL, et al. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm. 2012;430:292-299.
13. Fang JY, Fang CL, Liu CH, et al. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70: 633-640.
14. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454-477.
15. Löbenberg R, Maas J, Kreuter J. Improved body distribution of 14C-labelled AZT bound to nanoparticles in rats determined by radioluminography. J Drug Target. 1998;5:171-179.
16. Sawant RR, Vaze SO, Rockwell K, et al. Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel codelivery. Eur J Pharm Biopharm. 2010;75:321-326.
17. Shi F, Zhao JH, Liu Y, et al. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomedicine. 2012;7:2033-2043.
18. Gokce HE, Korkmaz E, Dellera E, et al. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine. 2012;7:1841-1850.
19. Gao DW, Tang SN, Tong Q. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. Int J Nanomedicine. 2012;7:3517-3526.
20. Elnaggar SY, El-Massik AM, Abdallah YO. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nano particles. Int J Nanomedicine. 2011;6: 3195-3205.
21. Chen CC, Tsai TH, Huang ZR, et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74:474-482.
22. Murakami K, Takahashi R, Ono M, et al. Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen. J Gastroenterol. 2011;46:1120-1126.
23. Brgles M, Jurašin D, Sikirić DM, et al. Entrapment of ovalbumin into liposomes - factors affecting entrapment efficiency, liposome size, and zeta potential. J Lipid Res. 2008;18:235-248.
24. Castelli F, Puglia C, Sarpietro GM, et al. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm. 2005;304:231-238.
25. Pardeike J, Weber S, Matsko N, et al. Formation of a physical stable delivery system by simply autoclaving nanostructured lipid carriers (NLC). Int J Pharm. 2012;439:22-27.